Daily Newsletter

30 September 2024

Daily Newsletter

30 September 2024

Medtronic’s PulseSelect system shows lesion durability in Afib treatment

The PulseSelect PFA system achieved a 98% success rate in maintaining pulmonary vein isolation.

RanjithKumar Dharma September 30 2024

Medtronic has announced new clinical study results showcasing a high durable lesion formation rate for the PulseSelect pulsed field ablation (PFA) system in atrial fibrillation (Afib) treatment.

The study, presented at the Asia Pacific Heart Rhythm Society meeting, indicated that 98% of pulmonary veins remained isolated approximately two months post-ablation.

The study involved 25 patients with persistent or paroxysmal Afib, demonstrating a 98% durability rate in pulmonary vein isolation (PVI) using the PulseSelect PFA system.

Invasive remapping conducted on average 57 days post-ablation showed that 96% of patients had all veins isolated.

All index ablation procedures were performed using intracardiac echocardiography and electroanatomical mapping, avoiding fluoroscopy.

The majority of patients were under general anaesthesia, and the average skin-to-skin procedure time was recorded at 36 minutes.

With acute PV isolation achieved in 100% of patients and no complications reported during an average follow-up of 74 days, the data underscores the system's safety and effectiveness.

Medtronic cardiovascular portfolio’s cardiac ablations solutions business president Rebecca Seidel said: “These important results clearly address the durability question and add to the real-world evidence for PulseSelect.

“With an expansion in new markets across the Asia Pacific region, physicians around the world are experiencing the benefits of PulseSelect, including proven safety, efficacy, efficiency and now durability as well. We are thrilled to provide this important tool to physicians for the treatment of patients with Afib.”

The PulseSelect PFA system has seen broad adoption, with more than 10,000 cases performed globally, including regulatory approvals and launches in the Asia Pacific region.

Afib affects over 60 million individuals worldwide and remains one of the most common yet undertreated heart rhythm disorders.

Before this development, Medtronic announced a partnership with Siemens Healthineers to expand access to advanced imaging technologies within the field of spine care.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close